New Method of SNP Typing in Aging Related Disorders

描述（由申请人提供）：本提案的目标是 将我们在I期研究中开发的一种新的检测方法商业化， 检测可能与衰老相关的遗传变异（SNP） 阿尔茨海默病、乳腺癌和心血管疾病等 疾病具体目标是进一步发展这一经济和 用于鉴定单核苷酸多态性的超灵敏平台 （SNP）。这种新方法将消除对PCR的典型要求 这是SNP测定中的扩增步骤，因此将理想地适用于 大群体的超高通量筛选。 该测定法基于使用寡核苷酸连接测定法（奥拉）、DNA连接测定法（DNA连接测定法）和DNA连接测定法。 微阵列，和我们的新的报告标签（PRP），允许超灵敏的 DNA的检测。 我们预计，我们的SBIR计划的完成将导致 使用试剂盒、方案和试剂进行SNP鉴定的商业化， 人口筛选和药物基因组学的销售给研究和 临床生物医学社区。 拟定商业应用： 销售试剂盒和试剂，这些试剂盒和试剂将成为筛选人群中与特定年龄相关疾病（如阿尔茨海默病、乳腺癌和心血管恶化）相关的SNP的首选方法。 设计便宜的用户友好的仪器，适用于个人医疗从业者，临床筛选实验室和研究设施。

DESCRIPTION (provided by applicant): The objectives of this proposal is to commercialize a novel assay we have developed in our phase I research for the detection of genetic variants (SNPs) that may be linked to aging related disorders such as Alzheimer's disease, breast cancer and cardiovascular disease. The specific aims are the further development of this economical and ultra-sensitive platform for identification of single nucleotide polymorphisms (SNPs). This new approach will eliminate the typical requirement for a PCR amplification step in SNP assays, and therefore will be ideally suited for ultra-high throughput screening of large populations. The assay is based on the use of an oligonucleotide ligation assay (OLA), a DNA microarray, and our novel reporter label (PRP) that allows for ultrasensitive detection of DNA. We expect that the completion of our SBIR program will result in the commercialization of SNP identification using kits, protocols, and reagents for population screening and pharmacogenomics for sale to both the research and clinical biomedical communities. PROPOSED COMMERCIAL APPLICATION: The sale of kits and reagents that will become the preferred methodology for the screening of human populations for SNPs associated with specific age related diseases, such as Alzheimer's, breast cancer, and cardiovascular deterioration. The design of inexpensive user-friendly instrumentation suitable for individual medical practioners, clinical screening laboratories, and research facilities.